Recurrent basal cell carcinoma treated with radiation therapy

Wilder, R. B.

doi:10.1001/archderm.127.11.1668

Cited by 17 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiotherapy is effective as primary treatment for BCC and SCC, with cure rates exceeding 90%, and generally equivalent to surgery 1,3 , 7,8 . Radiotherapy is also effective and appropriate for skin carcinomas that have recurred after previous surgical treatment 3,6 . For morphoeic BCC, Mohs' surgery is often stated to be the preferred method of treatment 1,9 but radiotherapy is an option if Mohs' surgery is not available or not desired by the patient 3,9 …”

Section: Discussionmentioning

confidence: 99%

“…comm., S Gauden, WP Holman Clinic, Launceston, 13 December 2002). Economic viability is certainly an issue; 1,2,5,6 , the purchase price of a new machine in 2002 is in the order of A$190 000 (pers. comm., N Atwood, CMS alphatech Limited, 18 November 2002), and to adequately service and maintain the machine to current quality assurance guidelines requires the services of a biomedical engineer and physicist 15 .…”

Section: Discussionmentioning

confidence: 99%

“…The use of superficial radiotherapy for skin disease has generally been in decline over recent decades. Once used widely for a variety of benign and malignant skin conditions, its use diminished with the availability of alternative effective treatments for skin disease, and community fears regarding adverse effects 1–6 . The high costs of capital equipment, parts and ongoing maintenance, have also been a factor 1,2 , 5,6 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Three‐year retrospective review of superficial radiotherapy for skin conditions in a Perth radiotherapy unit

Thom¹,

Heywood²,

Cassidy³

et al. 2003

Aust J Dermatology

View full text Add to dashboard Cite

Western Australia has only two superficial radiotherapy units, one of which is located at Fremantle Hospital, and run by the radiation oncologists of Perth Radiation Oncology Centre. A 3-year retrospective review was undertaken of all patients who underwent treatment at this unit from 1999 to 2001. Patients were identified from the unit's log book, and data was collected from their files. For malignant skin conditions, 369 lesions were treated in 259 patients over the study period. The patients' median age was 76 years. A wide variety of conditions were treated, but the most common diagnoses were basal cell carcinoma (237 lesions) and squamous cell carcinoma (92 lesions), most commonly located in the head region. The most frequently used treatment schedule was 36 Gy in six fractions over a 3-week period. Where radiotherapy was administered as primary treatment, the diagnoses had been biopsy-proven in only 53% of cases. Fifty-four patients underwent treatment of benign skin disease over the study period; most commonly keloid scars (41 patients) followed by warts (six patients). We conclude that superficial radiotherapy has a distinct role in dermatology, particularly for skin carcinomas around the nose and eyes, which cannot presently be superseded by electron beam therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Three‐year retrospective review of superficial radiotherapy for skin conditions in a Perth radiotherapy unit

Thom¹,

Heywood²,

Cassidy³

et al. 2003

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…In such instances, radiotherapy becomes an alternative approach for the treatment of invasive or inoperable BCCs, with 5 year tumor control rates of 89–100% (87–89). Also, radiotherapy plays an important role in the therapeutic strategy of recurrent BCC (90, 91) or morphea-type basal cell carcinoma (MBCC), which is a rare form of BCC with lower response to treatment than other histologic types (92). …”

Section: Introductionmentioning

confidence: 99%

Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis

Athar

2016

Radiation Research

View full text Add to dashboard Cite

This commentary summarizes studies showing risk of basal cell carcinoma (BCC) development in relationship to environmental, occupational and therapeutic exposure to ionizing radiation (IR). BCC, the most common type of human cancer, is driven by the aberrant activation of hedgehog (Hh) signaling. Ptch, a tumor suppressor gene of Hh signaling pathway, and Smoothened play a key role in the development of radiation-induced BCCs in animal models. Epidemiological studies provide evidence that humans exposed to radiation as observed among the long-term, large scale cohorts of atomic bomb survivors, bone marrow transplant recipients, patients with tinea capitis and radiologic workers enhances risk of BCCs. Overall, this risk is higher in Caucasians than other races. People who were exposed early in life develop more BCCs. The enhanced IR correlation with BCC and not other common cutaneous malignancies is intriguing. The mechanism underlying these observations remains undefined. Understanding interactions between radiation-induced signaling pathways and those which drive BCC development may be important in unraveling the mechanism associated with this enhanced risk. Recent studies showed that Vismodegib, a Smoothened inhibitor, is effective in treating radiation-induced BCCs in humans, suggesting that common strategies are required for the intervention of BCCs development irrespective of their etiology.

show abstract

“…PNI perineural invasion, Gy gray, post-op post-operative, LINAC linear accelerator a Dose-fractionation schedules using fraction sizes <4 Gy may reduce the risk of necrosis and ulceration b Only daily fraction sizes >6 Gy (p=0.0093) and treatment times <5 days (p=0.0053) were significantly associated with an increased risk of necrosis Radiotherapy is further a successful treatment modality in managing recurrent BCC following surgical excision. Such a scenario has produced 5-year cure rates of 95 [20], 88 [41], and 84 % [21] (although the last figure includes SCC, which typically has lower cure rates as discussed below). Cosmesis was observed to be good or acceptable in 93 % of patients [21].…”

Section: Radiotherapy Treatment Of Bccmentioning

confidence: 99%

Treatment of Non-Melanomatous Skin Cancer with Radiotherapy

et al. 2015

View full text Add to dashboard Cite

Non-melanomatous skin cancer (NMSC) is the leading cause of cancer in the United States. Treatment with surgical excision is considered the gold standard, but radiotherapy is an excellent alternative to surgical excision. Radiotherapy for NMSC takes many forms including a variety of external beam treatments as well as brachytherapy. Radiotherapy is indicated in a broad range of patients and is particularly useful in elderly patients who are poor surgical candidates or prefer not to have surgery. Radiotherapy is also employed in certain cases of recurrence and perineural invasion and when margin control is a concern. In addition to discussing standard techniques and indications for radiotherapy, this article will review specific considerations for radiotherapy in the treatment of basal cell carcinoma and squamous cell carcinoma. Finally, the article will examine new developments in the treatment of NMSC with radiotherapy including electronic brachytherapy and Helical TomoTherapy.

show abstract

Recurrent basal cell carcinoma treated with radiation therapy

Cited by 17 publications

References 0 publications

Three‐year retrospective review of superficial radiotherapy for skin conditions in a Perth radiotherapy unit

Three‐year retrospective review of superficial radiotherapy for skin conditions in a Perth radiotherapy unit

Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis

Treatment of Non-Melanomatous Skin Cancer with Radiotherapy

Contact Info

Product

Resources

About